ALK+ NSCLC Content | Docwire News

ALK+ NSCLC

Cecilia BrownNon-Small Cell Lung Cancer | January 13, 2025

The phase 2 trial included patients who had advanced or metastatic NSCLC with actionable genomic alterations.

Cecilia BrownALK+ NSCLC | December 19, 2024

The efficacy of ensartinib was evaluated in eXALT3, an open-label, randomized, active-controlled, multicenter trial.

Shirish M. Gadgeel, MDESMO 2024: Focus on Lung Cancer | January 6, 2025

Shirish M. Gadgeel, MD, discusses the phase 1/2 ARROS-1 and ALKOVE-1 studies presented at the ESMO 2024 Congress.

Ken Culver, MDWCLC 2024 | September 17, 2024

Ken Culver, MD, Director of Research and Clinical Affairs at ALK Positive, discusses the on-going ALK Life Study.